Cosunter(SZ:300436) Xin Hua Cai Jing·2025-08-01 08:31Core Viewpoint - The article highlights the significant stock price increase of Guangshentang, which achieved a 218.94% rise in July, driven by the surge in the innovative drug sector, despite the company facing continuous losses over the past four years [2][11]. Company Overview - Guangshentang, officially known as Fujian Guangshentang Pharmaceutical Co., Ltd., specializes in liver disease and antiviral treatments and is recognized as a national key high-tech enterprise [3]. - The company is transitioning from a traditional generic drug manufacturer to an innovative drug company, focusing on developing new drugs and high-end generics [3]. Financial Performance - Guangshentang has reported a cumulative loss of 664 million yuan over the past four years, with total losses reaching 695 million yuan when including the first quarter of this year [9]. - Despite the poor financial performance, the company has seen its stock price increase by over 250% year-to-date, ranking fifth in the innovative drug sector [11]. Innovative Drug Development - The company is advancing two innovative hepatitis B drugs, GST-HG141 and GST-HG131, which have shown promising clinical advantages and have been included in the list of breakthrough therapies [12][13]. - The innovative drug pipeline aims to address the limitations of current hepatitis B treatments, with the potential to become the first company globally to offer a cure for hepatitis B [14]. Market Context - The innovative drug sector is experiencing a boom, with significant interest from investors, despite some companies, including Guangshentang, facing ongoing financial challenges [11][14]. - The market for hepatitis B treatments is substantial, with millions of chronic patients in China, indicating a significant opportunity for successful drug development [13].